PE20000543A1 - Composiciones estabilizadas de quinapril y procedimiento para prepararlas - Google Patents
Composiciones estabilizadas de quinapril y procedimiento para prepararlasInfo
- Publication number
- PE20000543A1 PE20000543A1 PE1999000475A PE00047599A PE20000543A1 PE 20000543 A1 PE20000543 A1 PE 20000543A1 PE 1999000475 A PE1999000475 A PE 1999000475A PE 00047599 A PE00047599 A PE 00047599A PE 20000543 A1 PE20000543 A1 PE 20000543A1
- Authority
- PE
- Peru
- Prior art keywords
- cyclobraliphatic
- cycling
- refers
- quinapril
- preparing
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical group C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 title 1
- 229960001455 quinapril Drugs 0.000 title 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 abstract 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract 3
- 230000001351 cycling effect Effects 0.000 abstract 2
- 230000007062 hydrolysis Effects 0.000 abstract 2
- 238000006460 hydrolysis reaction Methods 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 108010061435 Enalapril Proteins 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 abstract 1
- 230000003276 anti-hypertensive effect Effects 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000002845 discoloration Methods 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960000873 enalapril Drugs 0.000 abstract 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 abstract 1
- 229950009810 indolapril Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000395 magnesium oxide Substances 0.000 abstract 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 abstract 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960003042 quinapril hydrochloride Drugs 0.000 abstract 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a)UN INHIBIDOR DE ENZIMA CONVERSORA DE ANGIOTENSINA (ACE) QUE ES SUSCEPTIBLE DE CICLACION, HIDROLISIS, DECOLORACION, DE FORMULA I, DONDE A ES UN ANILLO CICLOALIFATICO DE 5, 6 o 7 MIEMBROS, ANILLO BENCENO OPCIONALMENTE SUSTITUIDO CON ALCOXI C1-C4 O ESTA AUSENTE; n ES 0-1; R ES H, ALQUILO C1-C5, SIENDO DE PREFERENCIA EL INHIBIDOR CLORHIDRATO DE QUINAPRIL, ENALAPRIL, INDOLAPRIL; b)DE 1% A 90% DE UN ESTABILIZADOR TAL COMO OXIDO DE MAGNESIO PARA RETARDAR LA CICLACION Y LA DECOLORACION, c)UN AGENTE PARA INHIBIR LA HIDROLISIS QUE PUEDE SER UN SACARIDO TAL COMO MANITOL O LACTOSA, d)UNA DROGA ADICIONAL, e)LIGANTES, DESINTEGRANTES Y LUBRICANTES. TAMBIEN SE REFIERE A UN PROCESO PARA ESTABILIZAR LA COMPOSICION. LOS COMPUESTOS INHIBIDORES DE ACE SON UTILES COMO ANTIHIPERTENSIVOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8828098P | 1998-06-05 | 1998-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000543A1 true PE20000543A1 (es) | 2000-08-10 |
Family
ID=22210458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000475A PE20000543A1 (es) | 1998-06-05 | 1999-06-04 | Composiciones estabilizadas de quinapril y procedimiento para prepararlas |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US6417196B1 (es) |
| EP (1) | EP1083931B1 (es) |
| JP (1) | JP3727848B2 (es) |
| KR (1) | KR20010052557A (es) |
| CN (1) | CN1144598C (es) |
| AR (1) | AR019150A1 (es) |
| AT (1) | ATE295184T1 (es) |
| AU (1) | AU755616B2 (es) |
| BR (1) | BR9910947A (es) |
| CA (1) | CA2330581A1 (es) |
| CO (1) | CO5011043A1 (es) |
| DE (1) | DE69925269T2 (es) |
| ES (1) | ES2242398T3 (es) |
| GT (1) | GT199900079A (es) |
| HK (1) | HK1038879B (es) |
| HN (1) | HN1999000088A (es) |
| HU (1) | HUP0102260A3 (es) |
| ID (1) | ID27398A (es) |
| IL (1) | IL139590A0 (es) |
| IS (1) | IS2270B (es) |
| MY (1) | MY119667A (es) |
| NO (1) | NO20006148D0 (es) |
| NZ (1) | NZ508544A (es) |
| PA (1) | PA8475001A1 (es) |
| PE (1) | PE20000543A1 (es) |
| PL (1) | PL344586A1 (es) |
| SV (1) | SV1999000072A (es) |
| TR (1) | TR200003600T2 (es) |
| TW (1) | TW565455B (es) |
| UY (1) | UY25546A1 (es) |
| WO (1) | WO1999062560A1 (es) |
| ZA (1) | ZA200006537B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0102260A3 (en) * | 1998-06-05 | 2002-12-28 | Warner Lambert Co | Stabilization of compositions containing ace inhibitors using magnesium oxide |
| NZ333206A (en) * | 1998-12-08 | 2000-07-28 | Bernard Charles Sherman | Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor |
| GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| US7867514B2 (en) * | 2000-05-24 | 2011-01-11 | Otsuka Pharmaceutical Co., Ltd. | Method for stabilizing preparation |
| US20050118259A1 (en) * | 2002-01-15 | 2005-06-02 | Renir Eyjolfsson | Formulations of quinapril and related ace nhibitors |
| US20030157165A1 (en) * | 2002-02-01 | 2003-08-21 | Sherman Bernard Charles | Stable saccharide-free tablets comprising a salt of quinapril or moexipril |
| WO2004073729A1 (ja) * | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | 薬物の経鼻投与用組成物 |
| EP1607117A4 (en) | 2003-03-27 | 2007-10-24 | Bioactis Ltd | APPLICATOR FOR POWDER MEDICATION IN THE NOSE CAVE |
| CZ298224B6 (cs) * | 2003-04-29 | 2007-07-25 | Pliva Istrazivanje I Razvoj D.O.O. | Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby |
| ATE424192T1 (de) * | 2003-06-26 | 2009-03-15 | Teva Pharma | Stabile pharmazeutische zubereitungen mit 2-aza- bicyclo 3.3.0 -octan-3-carboxylsäure-derivaten |
| WO2006016530A1 (ja) * | 2004-08-10 | 2006-02-16 | Translational Research, Ltd. | 速効性でかつ高い吸収性を可能とする経鼻投与用組成物 |
| US8779175B2 (en) | 2004-10-25 | 2014-07-15 | Synthonics, Inc. | Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients |
| US7799937B2 (en) | 2004-10-25 | 2010-09-21 | Synthonics, Inc. | Metal coordinated compositions |
| US20060141054A1 (en) * | 2004-10-25 | 2006-06-29 | Thomas Piccariello | Metal coordinated compositions |
| ITMI20060026A1 (it) * | 2006-01-10 | 2007-07-11 | Truffini & Regge Farmaceutici Srl | Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento |
| EP1815857A1 (en) | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| US20070232680A1 (en) * | 2006-04-04 | 2007-10-04 | Vijayabhaskar Bolugoddu | Preparation of ramipril and stable pharmaceutical compositions |
| MX2008013374A (es) * | 2006-04-19 | 2008-11-12 | Teva Pharma | Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo[3.3.0]-octano-3-carboxilico. |
| WO2008000040A1 (en) * | 2006-06-30 | 2008-01-03 | Alphapharm Pty Ltd | A stabilised composition comprising ace inhibitors |
| US20080071141A1 (en) * | 2006-09-18 | 2008-03-20 | Abhisuek Gattani | Method and apparatus for measuring attributes of an anatomical feature during a medical procedure |
| WO2008078730A1 (ja) | 2006-12-26 | 2008-07-03 | Translational Research, Ltd. | 経鼻投与用製剤 |
| WO2008132756A1 (en) * | 2007-05-01 | 2008-11-06 | Lupin Limited | Stable pharmaceutical compositions of ramipril |
| JP5113476B2 (ja) * | 2007-10-09 | 2013-01-09 | 沢井製薬株式会社 | 保存安定性に優れた塩酸テモカプリルの錠剤 |
| US9101539B2 (en) * | 2009-05-15 | 2015-08-11 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
| WO2011013003A2 (en) | 2009-07-31 | 2011-02-03 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
| TR200906322A2 (tr) | 2009-08-17 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Çözünürlük ve stabilite özellikleri geliştirilmiş granüller. |
| ES2364011B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| CN102512656B (zh) * | 2011-12-27 | 2013-11-27 | 天津市嵩锐医药科技有限公司 | 盐酸喹那普利药物组合物 |
| US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3320029A (en) * | 1967-05-16 | Method of preparing magnesia | ||
| IL58849A (en) * | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
| US4344949A (en) * | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
| US4425355A (en) * | 1981-02-17 | 1984-01-10 | Warner-Lambert Company | Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids |
| US4793998A (en) * | 1986-10-20 | 1988-12-27 | Warner-Lambert Company | Stabilized drug compositions |
| US4830853A (en) | 1986-10-20 | 1989-05-16 | Warner-Lambert Company | Drug compositions stabilized against oxidation |
| US4743450A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
| US4830583A (en) * | 1988-03-02 | 1989-05-16 | Sri International | Fluid motor-pumping apparatus and system |
| US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
| HU222489B1 (hu) * | 1990-07-25 | 2003-07-28 | Novartis Ag. | Stabilizált gyógyszerkészítmények és eljárás az előállításukra |
| IT1251153B (it) * | 1991-08-06 | 1995-05-04 | Vectorpharma Int | Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica |
| JP3414539B2 (ja) * | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
| IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| HUP0102260A3 (en) * | 1998-06-05 | 2002-12-28 | Warner Lambert Co | Stabilization of compositions containing ace inhibitors using magnesium oxide |
| NZ333206A (en) * | 1998-12-08 | 2000-07-28 | Bernard Charles Sherman | Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor |
-
1999
- 1999-05-10 HU HU0102260A patent/HUP0102260A3/hu unknown
- 1999-05-10 NZ NZ508544A patent/NZ508544A/xx unknown
- 1999-05-10 ES ES99922899T patent/ES2242398T3/es not_active Expired - Lifetime
- 1999-05-10 PL PL99344586A patent/PL344586A1/xx not_active Application Discontinuation
- 1999-05-10 TR TR2000/03600T patent/TR200003600T2/xx unknown
- 1999-05-10 EP EP99922899A patent/EP1083931B1/en not_active Revoked
- 1999-05-10 IL IL13959099A patent/IL139590A0/xx not_active IP Right Cessation
- 1999-05-10 ID IDW20002515A patent/ID27398A/id unknown
- 1999-05-10 WO PCT/US1999/010189 patent/WO1999062560A1/en active IP Right Grant
- 1999-05-10 KR KR1020007013714A patent/KR20010052557A/ko not_active Application Discontinuation
- 1999-05-10 JP JP2000551814A patent/JP3727848B2/ja not_active Expired - Fee Related
- 1999-05-10 CA CA002330581A patent/CA2330581A1/en not_active Abandoned
- 1999-05-10 US US09/700,883 patent/US6417196B1/en not_active Expired - Fee Related
- 1999-05-10 AU AU39793/99A patent/AU755616B2/en not_active Ceased
- 1999-05-10 AT AT99922899T patent/ATE295184T1/de not_active IP Right Cessation
- 1999-05-10 DE DE69925269T patent/DE69925269T2/de not_active Revoked
- 1999-05-10 CN CNB998070262A patent/CN1144598C/zh not_active Expired - Fee Related
- 1999-05-10 BR BR9910947-6A patent/BR9910947A/pt not_active Application Discontinuation
- 1999-05-18 TW TW088108107A patent/TW565455B/zh not_active IP Right Cessation
- 1999-06-03 HN HN1999000088A patent/HN1999000088A/es unknown
- 1999-06-03 MY MYPI99002229A patent/MY119667A/en unknown
- 1999-06-04 SV SV1999000072A patent/SV1999000072A/es not_active Application Discontinuation
- 1999-06-04 PA PA19998475001A patent/PA8475001A1/es unknown
- 1999-06-04 AR ARP990102642A patent/AR019150A1/es not_active Application Discontinuation
- 1999-06-04 CO CO99035274A patent/CO5011043A1/es unknown
- 1999-06-04 UY UY25546A patent/UY25546A1/es not_active IP Right Cessation
- 1999-06-04 GT GT199900079A patent/GT199900079A/es unknown
- 1999-06-04 PE PE1999000475A patent/PE20000543A1/es not_active Application Discontinuation
-
2000
- 2000-11-10 ZA ZA200006537A patent/ZA200006537B/en unknown
- 2000-11-10 IS IS5712A patent/IS2270B/is unknown
- 2000-12-04 NO NO20006148A patent/NO20006148D0/no unknown
-
2002
- 2002-01-18 HK HK02100407.5A patent/HK1038879B/zh not_active IP Right Cessation
- 2002-04-22 US US10/127,181 patent/US7015232B2/en not_active Expired - Fee Related
-
2005
- 2005-12-15 US US11/313,123 patent/US20060106057A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000543A1 (es) | Composiciones estabilizadas de quinapril y procedimiento para prepararlas | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| UY28674A1 (es) | Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
| HUP0002960A2 (hu) | Aril-oxi-szulfonil-amino-hidroxámsav-származékok | |
| BG106020A (en) | Inhibitors of impdh enzyme | |
| BR0207871A (pt) | Composição para liberar bisfosfonato para um alvo | |
| NO991494L (no) | <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer | |
| PE20011001A1 (es) | Compuestos heterociclicos como inhibidores del intercambio de sodio/protones | |
| ATE273305T1 (de) | Thrombin-inhibitoren | |
| MX2007004783A (es) | Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan. | |
| TN2009000544A1 (fr) | Derives de benzimidazole | |
| ATE309999T1 (de) | Blutplättchen-adp-rezeptor-inhibitoren | |
| CO6190539A2 (es) | Composiciones de carbamato fenilalquilo | |
| ECSP088172A (es) | Metodos para tratar la epileptogenesis | |
| SV1997000026A (es) | Composiciones farmaceuticas para el tratamiento de la rinitis | |
| MA31775B1 (fr) | Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé | |
| BR0207644A (pt) | Compostos de carbamato para uso na prevenção ou no tratamento de distúrbio bipolar | |
| BR0213731A (pt) | Compostos de silìcio | |
| NO983444L (no) | Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer | |
| PT1305082E (pt) | Compostos de carbamato para utilizacao na prevencao ou tratamento da dor neuropatica e dor associada a cefaleia de salvas e enxaqueca | |
| AR007965A1 (es) | Composiciones plaguicidas que contienen diarilhidrazonas, dichas diarilhidrazonas, su preparacion, un metodo para combatir plagas con lasmismas, el material de propagacion de plantas tratado con dichos compuestos y su uso para controlar plagas. | |
| BR0107282A (pt) | Composto, composição farmacêutica e métodos para prevenir ou tratar uma condição em um mamìfero e para inibir a coagulação de amostras biológicas | |
| MA29567B1 (fr) | (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl) amino]-1,3-thiazol-4(5h)-one | |
| RU95110868A (ru) | Новые конденсированные производные тиазола, способ его получения и его фармацевтическая композиция | |
| DK1408954T3 (da) | Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af neuropatisk smerte |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |